Asset Details
Do you wish to reserve the book?
Meta-analysis of metabolic syndrome and prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Meta-analysis of metabolic syndrome and prostate cancer
Do you wish to request the book?
Meta-analysis of metabolic syndrome and prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Meta-analysis of metabolic syndrome and prostate cancer
2017
Overview
Background:
Metabolic syndrome (MetS) and prostate cancer (PCa) are highly prevalent conditions worldwide. Current evidence suggests the emerging hypothesis that MetS could play a role in the development and progression of several neoplasms. The aims of this study are to evaluate the impact of MetS and MetS factors on PCa incidence, on the risk of high-grade PCa and to analyze the role of MetS and single MetS components on the development of aggressive PCa features.
Methods:
A systematic literature search and analysis on PubMed, EMBASE, Cochrane and Academic One File databases until September 2015 was performed by 2 independent reviewers to evaluate the associations between MetS and PCa incidence, and between MetS and high-grade PCa incidence (bioptical Gleason Score⩾8, Prognostic Group 4–5 according to the novel prostate cancer grading system). Also the association between MetS and individual MetS components with pathological Gleason Score⩾8, extra-capsular extension, seminal vesicle invasion, positive surgical margins and biochemical recurrence (defined as two consecutive PSA values ⩾0.2 ng ml
−1
after radical prostatectomy) was evaluated.
Results:
24 studies were selected including a total of 132 589 participants of whom 17.35% had MetS. There was a slight association between MetS and PCa incidence (odds ratio (OR)=1.17 (1.00–1.36),
P
=0.04) and between high-grade PCa and MetS (OR= 1.89 (1.50–2.38),
P
<0.0001) but the studies were statistically heterogeneous. No association was found between MetS components and PCa risk except for hypertension. MetS was significantly associated with pathologic Gleason Score⩾8 (OR= 1.77 (1.34–2.34);
P
<0.01), extra-capsular extension (OR=1.13 (1.09–1.18);
P
<0.01), seminal vesicle invasion (OR=1.09 (1.07–1.12);
P
<0.01), positive surgical margins (OR=1.67 (1.47–1.91);
P
<0.01) and biochemical recurrence (OR=1.67 (1.04–2.69);
P
<0.01).
Conclusions:
The presence of MetS is associated with worse oncologic outcomes in men with PCa, in particular with more aggressive tumor features, and biochemical recurrence.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Analysis
/ Biomedical and Life Sciences
/ Humans
/ Male
/ Metabolic Syndrome - complications
/ Metabolic Syndrome - epidemiology
/ Metabolic Syndrome - pathology
/ Neoplasm Recurrence, Local - pathology
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - etiology
/ Prostatic Neoplasms - metabolism
/ Prostatic Neoplasms - pathology
/ review
/ Tumors
